Prelude Therapeutics Incorporated
NASDAQ:PRLD
1.27 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Prelude Therapeutics Incorporated |
Symbool | PRLD |
Munteenheid | USD |
Prijs | 1.27 |
Beurswaarde | 69,881,072 |
Dividendpercentage | 0% |
52-weken bereik | 1.1 - 6.8 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Website | https://www.preludetx.com |
An error occurred while fetching data.
Over Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)